🔎 Trials Near Me

Utama › Kanser Paru-paru Sel Kecil › Massachusetts

Kajian klinikal Kanser Paru-paru Sel Kecil di Massachusetts

22 kajian untuk Kanser Paru-paru Sel Kecil sedang mencari peserta di lokasi di Massachusetts.

Bandar di Massachusetts

Teks kajian rasmi (Bahasa Inggeris)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 19 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06586957

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Tufts Medical Center, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06047379

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  • Dana-Farber Cancer Institute /ID# 279690, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07365241

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

  • Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 hingga 100 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07006727

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05983432

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

  • Dana Farber Cancer Institute ( Site 1105), Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06780137

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Boston
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07038343

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center, Burlington
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06712355

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  • Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 hingga 100 · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06726148

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06095505

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Massachusetts General Hospital Cancer Center, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05592626

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  • Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06203210

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

  • Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06931626

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • Beth Israel Deaconess Medical Center, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06131840

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT05652686

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

  • Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Jun 2026 · NCT07149363

A Study of LY4175408 in Participants With Advanced Cancer

  • Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT07046923

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  • Tufts Medical Center, Boston
  • Lahey Hospital and Medical Center, Burlington
  • Lahey Medical Center-Peabody, Peabody
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Mac 2026 · NCT06769126

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Brigham and Women's Hospital, Boston
  • dan 1 lagi
Mengambil pesertaKajian pemerhatian
Umur 15 ke atas · Semua jantina · Dikemas kini 29 Okt 2025 · NCT05265429

DNA Analysis of Blood and Tissue from Patients with Lung Cancer

  • Massachusetts General Hospital, Boston
  • Harvard School of Public Health, Boston
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 120 · Semua jantina · Dikemas kini 29 Nov 2024 · NCT00471978

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.